Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 243.73 Billion KRW | 19.02% |
| 2022 | 204.78 Billion KRW | -3.03% |
| 2021 | 211.17 Billion KRW | 72.47% |
| 2020 | 122.44 Billion KRW | -0.71% |
| 2019 | 123.31 Billion KRW | 33.69% |
| 2018 | 92.24 Billion KRW | 56.15% |
| 2017 | 59.07 Billion KRW | 12.16% |
| 2016 | 52.66 Billion KRW | 14.28% |
| 2015 | 46.08 Billion KRW | -0.04% |
| 2014 | 46.1 Billion KRW | 24.99% |
| 2013 | 36.88 Billion KRW | 7.86% |
| 2012 | 34.2 Billion KRW | -6.23% |
| 2011 | 36.47 Billion KRW | 7.88% |
| 2010 | 33.8 Billion KRW | 1.91% |
| 2009 | 33.17 Billion KRW | 48.67% |
| 2008 | 22.31 Billion KRW | 24.8% |
| 2007 | 17.88 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 278.21 Billion KRW | 14.15% |
| 2024 Q2 | 302.86 Billion KRW | 8.86% |
| 2023 Q2 | 200.03 Billion KRW | -2.47% |
| 2023 Q4 | 243.73 Billion KRW | 13.4% |
| 2023 FY | 243.73 Billion KRW | 19.02% |
| 2023 Q1 | 205.09 Billion KRW | 0.15% |
| 2023 Q3 | 214.92 Billion KRW | 7.45% |
| 2022 Q1 | 225.15 Billion KRW | 6.62% |
| 2022 FY | 204.78 Billion KRW | -3.03% |
| 2022 Q4 | 204.78 Billion KRW | -8.73% |
| 2022 Q3 | 224.36 Billion KRW | 0.41% |
| 2022 Q2 | 223.44 Billion KRW | -0.76% |
| 2021 FY | 211.17 Billion KRW | 72.47% |
| 2021 Q2 | 183.25 Billion KRW | 27.02% |
| 2021 Q1 | 144.27 Billion KRW | 17.83% |
| 2021 Q3 | 204.9 Billion KRW | 11.81% |
| 2021 Q4 | 211.17 Billion KRW | 3.06% |
| 2020 FY | 122.44 Billion KRW | -0.71% |
| 2020 Q4 | 122.44 Billion KRW | -1.64% |
| 2020 Q2 | 118.62 Billion KRW | -4.67% |
| 2020 Q3 | 124.48 Billion KRW | 4.94% |
| 2020 Q1 | 124.43 Billion KRW | 0.91% |
| 2019 Q3 | 115.01 Billion KRW | 1.74% |
| 2019 Q2 | 113.05 Billion KRW | 2.45% |
| 2019 FY | 123.31 Billion KRW | 33.69% |
| 2019 Q4 | 123.31 Billion KRW | 7.21% |
| 2019 Q1 | 110.34 Billion KRW | 19.63% |
| 2018 Q4 | 92.24 Billion KRW | 26.62% |
| 2018 FY | 92.24 Billion KRW | 56.15% |
| 2018 Q1 | 71.66 Billion KRW | 21.32% |
| 2018 Q2 | 69.95 Billion KRW | -2.38% |
| 2018 Q3 | 72.85 Billion KRW | 4.14% |
| 2017 Q1 | 57.45 Billion KRW | 9.08% |
| 2017 Q4 | 59.07 Billion KRW | -6.68% |
| 2017 FY | 59.07 Billion KRW | 12.16% |
| 2017 Q2 | 63.08 Billion KRW | 9.8% |
| 2017 Q3 | 63.3 Billion KRW | 0.35% |
| 2016 Q2 | 50.19 Billion KRW | 0.47% |
| 2016 FY | 52.66 Billion KRW | 14.28% |
| 2016 Q1 | 49.96 Billion KRW | 8.41% |
| 2016 Q4 | 52.66 Billion KRW | 11.99% |
| 2016 Q3 | 47.02 Billion KRW | -6.31% |
| 2015 FY | 46.08 Billion KRW | -0.04% |
| 2015 Q3 | 41.22 Billion KRW | -1.12% |
| 2015 Q4 | 46.08 Billion KRW | 11.8% |
| 2015 Q2 | 41.68 Billion KRW | -16.34% |
| 2015 Q1 | 49.82 Billion KRW | 8.08% |
| 2014 Q1 | 41.7 Billion KRW | 13.06% |
| 2014 FY | 46.1 Billion KRW | 24.99% |
| 2014 Q4 | 46.1 Billion KRW | 15.77% |
| 2014 Q3 | 39.82 Billion KRW | 2.94% |
| 2014 Q2 | 38.68 Billion KRW | -7.23% |
| 2013 Q3 | 35.7 Billion KRW | -2.96% |
| 2013 Q2 | 36.79 Billion KRW | 6.25% |
| 2013 Q4 | 36.88 Billion KRW | 3.31% |
| 2013 FY | 36.88 Billion KRW | 7.86% |
| 2013 Q1 | 34.63 Billion KRW | 1.26% |
| 2012 Q1 | 37.79 Billion KRW | 0.0% |
| 2012 FY | 34.2 Billion KRW | -6.23% |
| 2012 Q4 | 34.2 Billion KRW | 0.0% |
| 2011 FY | 36.47 Billion KRW | 7.88% |
| 2011 Q2 | 33.43 Billion KRW | -10.4% |
| 2011 Q1 | 37.31 Billion KRW | 10.36% |
| 2011 Q3 | 33.55 Billion KRW | 0.38% |
| 2010 Q3 | 32.7 Billion KRW | 7.97% |
| 2010 Q1 | 35.09 Billion KRW | 5.78% |
| 2010 FY | 33.8 Billion KRW | 1.91% |
| 2010 Q4 | 33.8 Billion KRW | 3.36% |
| 2010 Q2 | 30.29 Billion KRW | -13.67% |
| 2009 Q3 | 24.07 Billion KRW | -0.68% |
| 2009 FY | 33.17 Billion KRW | 48.67% |
| 2009 Q4 | 33.17 Billion KRW | 37.8% |
| 2009 Q1 | 25.75 Billion KRW | 15.43% |
| 2009 Q2 | 24.24 Billion KRW | -5.88% |
| 2008 Q3 | 23.06 Billion KRW | 2.6% |
| 2008 Q1 | 21.66 Billion KRW | 21.19% |
| 2008 FY | 22.31 Billion KRW | 24.8% |
| 2008 Q2 | 22.48 Billion KRW | 3.75% |
| 2008 Q4 | 22.31 Billion KRW | -3.26% |
| 2007 Q1 | 16.15 Billion KRW | 0.0% |
| 2007 Q4 | 17.88 Billion KRW | -12.31% |
| 2007 FY | 17.88 Billion KRW | 0.0% |
| 2007 Q2 | 14.21 Billion KRW | -12.03% |
| 2007 Q3 | 20.39 Billion KRW | 43.47% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -213.05% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 73.786% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 65.53% |
| HANDOK Inc. | 449.7 Billion KRW | 45.802% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -184.502% |
| Yuhan Corporation | 712.33 Billion KRW | 65.784% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 61.429% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -1433.449% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 71.387% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -355.334% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -18.389% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -224.239% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -64.914% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -246.207% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -213.05% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -568.932% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 2.953% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -10.434% |
| JW Holdings Corporation | 827.51 Billion KRW | 70.546% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 44.225% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 58.463% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 35.792% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -207.351% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -248.352% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -0.363% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 26.207% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -213.05% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 50.26% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 71.594% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 35.792% |
| Yuhan Corporation | 712.33 Billion KRW | 65.784% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 48.989% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -77.949% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 52.826% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 35.792% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -57.72% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -170.92% |
| CKD Bio Corp. | 170.76 Billion KRW | -42.734% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -54.598% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -466.571% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -207.351% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 61.466% |
| Boryung Corporation | 373.1 Billion KRW | 34.675% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -17.069% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -18.389% |
| JW Lifescience Corporation | 96.44 Billion KRW | -152.723% |